Clinical Trials Browser

NIH × Pancreatic Neoplasms × LMB-100 × Clear all

NCT02810418 2022-03-15

Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors

Phase 1/2 Completed

40 enrolled 37 charts

Gastrointestinal

Neoplasms, Pancreatic Neoplasms